The role of macrolide antibiotics in increasing cardiovascular risk

Journal of the American College of Cardiology

Volumn 66, Issue 20, 2015, Pages 2173-2184

  Cheng, Yun Jiu ^a   Nie, Xiao Ying ^a   Chen, Xu Miao ^a   Lin, Xiao Xiong ^a   Tang, Kai ^a   Zeng, Wu Tao ^a   Mei, Wei Yi ^a   Liu, Li Juan ^a   Long, Ming ^a   Yao, Feng Juan ^a   Liu, Jun ^a   Liao, Xin Xue ^a   Du, Zhi Min ^a   Dong, Yu Gang ^a   Ma, Hong ^a   Xiao, Hai Peng ^a   Wu, Su Hua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

coronary heart disease; roxithromycin; sudden cardiac death; ventricular tachyarrhythmia

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; PENICILLIN DERIVATIVE; ROXITHROMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; ASSESSMENT OF HUMANS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DRUG SAFETY; DRUG USE; HEART DISEASE; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE TACHYCARDIA; HIGH RISK POPULATION; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; NEWCASTLE OTTAWA QUALITY ASSESSMENT SCALE; PATIENT SAFETY; PRIORITY JOURNAL; PUBLISHING; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SUDDEN CARDIAC DEATH; TREATMENT DURATION; TREND STUDY; DEATH, SUDDEN, CARDIAC; FEMALE; MALE; RISK FACTOR; TACHYCARDIA, VENTRICULAR;

ANTI-BACTERIAL AGENTS; CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; FEMALE; HUMANS; MACROLIDES; MALE; RISK FACTORS; TACHYCARDIA, VENTRICULAR;

EID: 84946730330     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.09.029     Document Type: Article

References (31)

1. R.J. Owens, and T.D. Nolin Antimicrobial-associated QT interval prolongation: pointes of interest Clin Infect Dis 43 2006 1603 1611
2. B.H. Huang, C.H. Wu, C.P. Hsia, and C.C. Yin Azithromycin-induced torsade de pointes Pacing Clin Electrophysiol 30 2007 1579 1582
3. W.A. Ray, K.T. Murray, S. Meredith, and et al. Oral erythromycin and the risk of sudden death from cardiac causes N Engl J Med 351 2004 1089 1096
4. W.A. Ray, K.T. Murray, K. Hall, and et al. Azithromycin and the risk of cardiovascular death N Engl J Med 366 2012 1881 1890
5. H. Svanstrom, B. Pasternak, and A. Hviid Use of azithromycin and death from cardiovascular causes N Engl J Med 368 2013 1704 1712
6. E.M. Mortensen, E.A. Halm, M.J. Pugh, and et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia JAMA 311 2014 2199 2208
7. A.B. Suthar, N. Ford, P.J. Bachanas, and et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches PLoS Med 10 2013 e1001496
8. R. Boussageon, T. Bejan-Angoulvant, M. Saadatian-Elahi, and et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials BMJ 343 2011 d4169
9. Y.J. Cheng, Z.H. Liu, F.J. Yao, and et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis PLoS Med 10 2013 e1001515
10. T. Stijnen, T.H. Hamza, and P. Ozdemir Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data Stat Med 29 2010 3046 3067
11. Y.J. Cheng, J. Zhang, W.J. Li, and et al. More favorable response to cardiac resynchronization therapy in women than in men Circ Arrhythm Electrophysiol 7 2014 807 815
12. S.H. Wu, X.X. Lin, Y.J. Cheng, and et al. Early repolarization pattern and risk for arrhythmia death: a meta-analysis J Am Coll Cardiol 61 2013 645 650
13. E. Poluzzi, E. Raschi, U. Moretti, and F. De Ponti Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS) Pharmacoepidemiol Drug Saf 18 2009 512 518
14. W.I. Sligl, L. Asadi, D.T. Eurich, and et al. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis Crit Care Med 42 2014 420 432
15. S. Kudoh, A. Azuma, M. Yamamoto, and et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin Am J Respir Crit Care Med 157 1998 1829 1832
16. P. Kannankeril, D.M. Roden, and D. Darbar Drug-induced long QT syndrome Pharmacol Rev 62 2010 760 781
17. C. Antzelevitch, Z.Q. Sun, Z.Q. Zhang, and G.X. Yan Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes J Am Coll Cardiol 28 1996 1836 1848
18. R.K. Albert, and J.L. Schuller Macrolide antibiotics and the risk of cardiac arrhythmias Am J Respir Crit Care Med 189 2014 1173 1180
19. J. Guo, S. Zhan, J.P. Lees-Miller, and et al. Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C Heart Rhythm 2 2005 860 866
20. P. Korantzopoulos, K.P. Letsas, Z. Christogiannis, and et al. Exercise-induced repolarization changes in patients with stable coronary artery disease Am J Cardiol 107 2011 37 40
21. P.E. Lazzerini, P.L. Capecchi, M. Acampa, and et al. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation Autoimmun Rev 13 2014 936 944
22. M. Bilgin, A. Akyel, M. Dogan, and et al. Acute coronary syndrome secondary to clarithromycin: the first case and review of the literature Turk Kardiyol Dern Ars 42 2014 461 463
23. B.S. Murphy, V. Sundareshan, T.J. Cory, and et al. Azithromycin alters macrophage phenotype J Antimicrob Chemother 61 2008 554 560
24. M. Vrancic, M. Banjanac, K. Nujic, and et al. Azithromycin distinctively modulates classical activation of human monocytes in vitro Br J Pharmacol 165 2012 1348 1360
25. H. Ohtani, C. Taninaka, E. Hanada, and et al. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats Antimicrob Agents Chemother 44 2000 2630 2637
26. W.A. Volberg, B.J. Koci, W. Su, and et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics J Pharmacol Exp Ther 302 2002 320 327
27. S.S. Chugh, J. Jui, K. Gunson, and et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community J Am Coll Cardiol 44 2004 1268 1275
28. R.R. Makkar, B.S. Fromm, R.T. Steinman, and et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs JAMA 270 1993 2590 2597
29. D. Zeltser, D. Justo, A. Halkin, and et al. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors Medicine (Baltimore) 82 2003 282 290
30. J.T. Grayston, R.A. Kronmal, L.A. Jackson, and et al. Azithromycin for the secondary prevention of coronary events N Engl J Med 352 2005 1637 1645
31. S. Gupta, E.W. Leatham, D. Carrington, and et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction Circulation 96 1997 404 407